Therapeutic Solutions International Inc (TSOI)

[centsability4me]

TSOI Recap

TSI has several intellectual properties being developed - (working their way through the patent process) , at this time .

The patent info is listed here :

http://therapeuticsolutionsint.com/?page_id=120

Re: Clinical Stage Dexosome


TSOI recently licensed January 2016 a Dexosome Clinical Stage Cancer Immunotherapy Product from Gustave Roussy European Cancer Centre. Planning is still underway as to next steps.



Re: CAPO ,MVAX :
(from the recent 10K)

MolecuVax, Inc.


The Company previously announced that MolecuVax, Inc. (MVAX) was a partially-owned subsidiary of TSOI. On September 30, 2016, Mr. Gerry Berg, and Mr. Timothy Dixon resigned as Officers and Directors of MVAX and cancelled any and all equity in MVAX and have asserted certain contractual rights of our licensed patent to MVAX dated February 5 th , 2016. Our departure and subsequent cancellation of stock was due to an attempt at a hostile take-over of the Board of Directors of MVAX by other board members. In addition, on October 12, 2016, Dr. Thomas Ichim also resigned from MVAX as CEO and Director.


Capo Therapeutics, Inc.


The Company previously announced that TSOI held an equity stake in Capo Therapeutics, Inc. (CAPO). On September 30, 2016, Mr. Gerry Berg, and Mr. Timothy Dixon resigned as Officers and Directors of CAPO and cancelled any and all equity in CAPO. Our departure and subsequent cancellation of stock was due to an attempt at a hostile take-over of the Board of Directors of CAPO by other board members.

Re: OMNI :

As of July 20, 2016 TSI owns approximately 73.75% of the outstanding shares of OmniBiome, Inc.

OmniBiome Inc. continues as a subsidiary of TSI .

OMNI is focused on fetal /maternal health issues , as well as a periodontal paste being developed . TSI licensed 3 patents to OMNI .

http://omnibiomeinc.com/?page_id=18

1) Prevention of Pregnancy Complications by Probiotic Administration
2) Cytokine Modulation to Prevent Pregnancy Loss and Pre-Term Labor
3)Cytokine based diagnostic test

Re: Filings :

The filings are 3 quarters back .( TSI was 3 years behind in it's filings , so they have made good progress toward compliance , and the audits are ongoing.

Re: Nutraceuticals :

TSI recently added liposomals to their nutraceutical product line . These products have been developed and manufactured ,and are available at their E commerce site :

http://www.youcanordernow.com/

Re: Reverse split :
(From the 10K)



On August 22, 2016, the Board of Directors deemed it to be in the best interest of the Company to affect a reverse stock-split of its common stock of one (1) new common share for each two (2) old common shares of stock, subject to approval by a majority of shareholders. If sufficient votes are not obtained from a majority of shareholders, this action will become cancelled as of October 31, 2016.